Champions Oncology Reports 13.5% Revenue Growth and Net Income Turnaround for Fiscal Year Ending April 30, 2025

Champions Oncology, Inc. reported a financial performance for the fiscal year ending April 30, 2025, with total revenues reaching approximately $56.9 million, marking a 13.5% increase from the previous year's revenue of $50.2 million. The company achieved a net income of approximately $4.7 million, a significant turnaround from a net loss of $7.3 million in the prior fiscal year. This improvement in profitability was attributed to enhanced operational efficiencies and a stronger conversion rate of bookings to revenue, particularly in its pharmacology services segment, which generated $48.6 million in revenue.

The company also noted a decrease in total costs and operating expenses, which fell by 8.9% to $52.4 million from $57.5 million in the previous year. This reduction was driven by lower costs associated with oncology revenue, which decreased by 3.4% to $28.4 million, as well as a significant cut in research and development expenses, which dropped by 28.5% to $6.8 million. The decrease in R&D spending reflects a strategic decision to focus resources more effectively, particularly in light of the company's ongoing efforts to expand its TumorBank and enhance its technology platforms.

Champions Oncology has made notable strides in its operational developments, including the expansion of its TumorBank, which now includes approximately 1,500 Patient Derived Xenograft (PDX) models. The company has also increased its customer base, having performed studies for around 500 different pharmaceutical and biotechnology companies over the past decade. The company’s SaaS platform, Lumin Bioinformatics, continues to evolve, although it experienced a slight decline in subscription revenues during the fiscal year. The total employee headcount as of July 15, 2025, stood at 213, with a significant portion engaged in research and development.

Looking ahead, Champions Oncology aims to leverage its technology platforms to drive multiple revenue streams and establish a global leadership position in oncology research. The company plans to continue investing in research and development to enhance its offerings and expand its market share. Despite the positive financial results, the company acknowledges the need for ongoing capital to support its growth initiatives and has indicated that it may seek additional funding if necessary. The management remains optimistic about the future, projecting that current cash reserves and operational cash flows will sustain the company through at least August 2026.